BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.

Abstract excerpt

Approximately 5-10% of breast carcinomas and 10% of ovarian carcinomas are ascribable to a genetic susceptibility. Of these, about 40% are related to genetic mutations in the genes BRCA1 and BRCA2. Despite the increasing demand for genetic testing arising from the patients and their relatives, the genetic testing can be offered yet only to individuals belonging to high-risk families in which the probability that...

Topics

Join the communities discussing this publication.

• BRCA1 Protein
• BRCA2 Protein
• Breast Neoplasms
• DNA Mutational Analysis
• BRCA2 gene